Correction to: An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB (Nature Medicine, (2010), 16, 3, (286-294), 10.1038/nm.2100);An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-B

Nature Medicine

Volumn 16, Issue 3, 2010, Pages 286-294

  Min, Junxia ^a,b   Zaslavsky, Alexander ^c   Fedele, Giuseppe ^b,d   McLaughlin, Sara K ^a,b   Reczek, Elizabeth E ^a,b   De Raedt, Thomas ^a,b   Guney, Isil ^b,d   Strochlic, David E ^b,d   MacConaill, Laura E ^d   Beroukhim, Rameen ^b,d,e   Bronson, Roderick T ^b   Ryeom, Sandra ^c   Hahn, William C ^b,d,e   Loda, Massimo ^a,b,d,e   Cichowski, Karen ^a,b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAB21P PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE LOSS; GENE SILENCING; IN VITRO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

EID: 77749297990     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-024-02866-2     Document Type: Erratum

References (50)

1. Nelson, W.G., De Marzo, A.M. & Isaacs, W.B. Prostate cancer. N. Engl. J. Med. 349, 366-381 (2003)
2. Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008)
3. Jeong, J.H. et al. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One 3, e3949 (2008)
4. Shen, M.M. & Abate-Shen, C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res. 67, 6535-6538 (2007)
5. Gioeli, D., Mandell, J.W., Petroni, G.R., Frierson, H.F. Jr. & Weber, M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59, 279-284 (1999)
6. Malik, S.N. et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 8, 1168-1171 (2002)
7. Carter, B.S., Epstein, J.I. & Isaacs, W.B. ras gene mutations in human prostate cancer. Cancer Res. 50, 6830-6832 (1990)
8. Gumerlock, P.H., Poonamallee, U.R., Meyers, F.J. & deVere White, R.W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 51, 1632-1637 (1991)
9. Cho, N.Y. et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int. J. Cancer 119, 1858-1862 (2006)
10. Bernards, A. & Settleman, J. GEFs in growth factor signaling. Growth Factors 25, 355-361 (2007)
11. Bernards, A. & Settleman, J. GAPs in growth factor signaling. Growth Factors 23, 143-149 (2005)
12. Riccardi, V.M. Neurofbromatosis: Phenotype, Natural History and Pathogenesis. Ch. 3 (The Johns Hopkins University Press, Baltimore, 1992)
13. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008)
14. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008)
15. McGillicuddy, L.T. et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16, 44-54 (2009)
16. Johannessen, C.M. et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 102, 8573-8578 (2005)
17. von Bergh, A.R. et al. Identifcation of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosom. Cancer 39, 324-334 (2004)
18. Dote, H. et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin. Cancer Res. 10, 2082-2089 (2004)
19. Dote, H. et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br. J. Cancer 92, 1117-1125 (2005) (Pubitemid 40546678)
20. Yano, M. et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int. J. Cancer 113, 59-66 (2005) (Pubitemid 39507311)
21. Chen, H., Tu, S.W. & Hsieh, J.T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem. 280, 22437-22444 (2005)
22. Ke, X.S. et al. Genome-wide profling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 4, e4687 (2009)
23. Berger, R. et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 64, 8867-8875 (2004)
24. Arai, Y. et al. Radical prostatectomy for clinically localized prostate cancer: local tumor extension and prognosis. Int. J. Urol. 3, 373-378 (1996)
25. Sørensen, H.T., Mellemkjaer, L., Olsen, J.H. & Baron, J.A. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846-1850 (2000)
26. Scheel, C., Onder, T., Karnoub, A. & Weinberg, R.A. Adaptation versus selection: the origins of metastatic behavior. Cancer Res. 67, 11476-11479, discussion 11479-11480 (2007)
27. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454 (2002)
28. Weinberg, R.A. The Biology of Cancer. (Garland Science, New York, 2007)
29. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004)
30. Joyce, J.A. & Pollard, J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252 (2009)
31. Zhang, H. et al. AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J. Biol. Chem. 279, 44955-44965 (2004)
32. Huber, M.A., Beug, H. & Wirth, T. Epithelial-mesenchymal transition: NF-κB takes center stage. Cell Cycle 3, 1477-1480 (2004)
33. Naugler, W.E. & Karin, M. NF-κB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19-26 (2008)
34. Hayden, M.S. & Ghosh, S. Shared principles in NF-κB signaling. Cell 132, 344-362 (2008)
35. Mayo, M.W. et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812-1815 (1997)
36. Simon, J.A. & Lange, C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647, 21-29 (2008)
37. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002)
38. Yu, J. et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67, 10657-10663 (2007)
39. Kondo, Y. et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40, 741-750 (2008)
40. Vanaja, D.K., Cheville, J.C., Iturria, S.J. & Young, C.Y. Transcriptional silencing of zinc fnger protein 185 identifed by expression profling is associated with prostate cancer progression. Cancer Res. 63, 3877-3882 (2003)
41. Lapointe, J. et al. Gene expression profling identifes clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 101, 811-816 (2004)
42. Tomlins, S.A., Rubin, M.A. & Chinnaiyan, A.M. Integrative biology of prostate cancer progression. Annu. Rev. Pathol. 1, 243-271 (2006)
43. Luo, J.H. et al. Gene expression analysis of prostate cancers. Mol. Carcinog. 33, 25-35 (2002)
44. Daskivich, T.J. & Oh, W.K. Recent progress in hormonal therapy for advanced prostate cancer. Curr. Opin. Urol. 16, 173-178 (2006)
45. Abate-Shen, C. & Shen, M.M. Mouse models of prostate carcinogenesis. Trends Genet. 18, S1-S5 (2002)
46. Wang, S. et al. Prostate-specifc deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 (2003)
47. Henry, D.O. et al. Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol. Cell. Biol. 20, 8084-8092 (2000)
48. Barbie, D.A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009)
49. Sellers, W.R. & Loda, M. The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer? Cancer Cell 2, 349-350 (2002)
50. Chen, H., Toyooka, S., Gazdar, A.F. & Hsieh, J.T. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J. Biol. Chem. 278, 3121-3130 (2003)